Research programme: psoriasis therapies - GroPep

Drug Profile

Research programme: psoriasis therapies - GroPep

Alternative Names: pp 0102; PP-0102

Latest Information Update: 04 Feb 2011

Price : $50

At a glance

  • Originator Northern Sydney Health
  • Class Peptides
  • Mechanism of Action T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Psoriasis

Most Recent Events

  • 04 Feb 2011 Discontinued - Preclinical for Psoriasis in Australia (Topical)
  • 21 Mar 2006 PP 0102 is available for licensing (
  • 31 Dec 2003 Preclinical trials in Skin disorders in Australia (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top